Half-year report · Q2
2934.TEDINET S100VCMY
Period2024-06-01 → 2024-11-30
Filed2025-03-06
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Amends S100V313. Amended by S100VCX6 (2025-03-06).
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.8bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥17.7bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.0bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Operating income | ¥131m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Operating income | −¥221m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Ordinary income | ¥112m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | −¥643m | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥232m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥118m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Profit before tax | −¥233m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥8m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.1bn | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥287m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥53m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Net income | −¥284m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Total assets | ¥9.1bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥10.7bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥7.4bn | at 2023-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.5bn | at 2024-11-30 | Cons. | Liabilities |
| Total liabilities | ¥9.1bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.7bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥1.6bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2023-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.9bn | at 2024-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥13m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥971m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥220m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.8bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥300m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥139m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥933m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥1.58 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-426.06 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-59.33 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥1.56 | 2024-06-01 → 2024-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 12.7% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 10.8% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥180m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥4.7bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥4.6bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥96m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥24m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥11m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥100m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥2m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥236m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥11.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥10.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥109m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥312m |
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥290m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.4bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.3bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥114m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥19m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥6m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥958,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥44m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-11-30 | ¥8.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-11-30 | ¥8.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥115m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-11-30 | ¥69m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 533
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)監査法人アヴァンティア | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)相 馬 裕 晃 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)橋 本 剛 | |
| Number of submission | FilingDateInstant | 3 | |
| Net sales (5-year summary) | Prior1YTDDuration | 8013983000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 10843838000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 17714904000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | -232098000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 111520000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | -642540000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | -286515000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 7850000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | -2086426000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | -284370000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 49491000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | -2030372000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 3124440000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 1672842000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 1620898000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 7359948000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 9142449000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 10713787000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | -59.33 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 1.58 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | -426.06 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | 1.56 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.391 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.127 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.108 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | -970999000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | -12768000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | -1435744000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -300338000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | 219691000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -1792539000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | 933186000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -139171000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 3390891000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 1250209000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 1820717000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 1752966000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 5147096 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 5147096 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 5147096 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 5147096 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 2369000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.4769 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |